stockportfolio.pro
Stocks / QDEL vs SPRY
QDEL vs SPRY
QuidelOrtho Corporation and ARS Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| QuidelOrtho Corporation (QDEL) | ARS Pharmaceuticals, Inc. (SPRY) | |
|---|---|---|
| Market cap | $0.9B | $0.9B |
| Revenue (latest FY) | $2.73B | $84.28M |
| Net income (latest FY) | $-1.13B | $-171.30M |
| Revenue growth (5y CAGR) | 10.4% | — |
| Net margin | -41.5% | -203.3% |
| Return on equity | -58.9% | -149.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open QDEL — free Open SPRY — freeFrequently asked questions
Which is bigger, QDEL or SPRY?
ARS Pharmaceuticals, Inc. is larger by market capitalization — $0.9B versus $0.9B.
Which grows faster, QDEL or SPRY?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.